Literature DB >> 3729726

Effect of interferon on Vero cells persistently infected with SSPE virus and lytically infected with measles virus.

M Crespi, M N Chiu, B D Schoub, S F Lyons.   

Abstract

The effect of lymphoblastoid interferon (IFN) on viral polypeptides synthesized in a Vero cell culture persistently infected with subacute sclerosing panencephalitis virus (SSPE-Vero) was compared to that of Vero cells infected with exogenous measles virus. After IFN treatment there was no significant decrease in the synthesis of SSPE viral proteins, but inhibition of synthesis of measles polypeptides was readily seen. In Vero and SSPE-Vero cells IFN was able to inhibit replication of Sindbis virus although the effect in Vero cells was significantly more sensitive. In both cell lines IFN was able to stimulate 2'--5' oligoadenylate synthetase (E enzyme) but not the protein kinase system. The SSPE-Vero cells showed a lower basal level of E enzyme activity than the Vero cells.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 3729726     DOI: 10.1007/bf01314147

Source DB:  PubMed          Journal:  Arch Virol        ISSN: 0304-8608            Impact factor:   2.574


  25 in total

1.  Additional evidence of the relation between subacute inclusion-body encephalitis and measles virus.

Authors:  J M Freeman; R L Magoffin; E H Lennette; R M Herndon
Journal:  Lancet       Date:  1967-07-15       Impact factor: 79.321

2.  A film detection method for tritium-labelled proteins and nucleic acids in polyacrylamide gels.

Authors:  W M Bonner; R A Laskey
Journal:  Eur J Biochem       Date:  1974-07-01

3.  Cleavage of structural proteins during the assembly of the head of bacteriophage T4.

Authors:  U K Laemmli
Journal:  Nature       Date:  1970-08-15       Impact factor: 49.962

4.  Procedures for measurement of phosphorylation of ribosome-associated proteins in interferon-treated cells.

Authors:  C E Samuel
Journal:  Methods Enzymol       Date:  1981       Impact factor: 1.600

Review 5.  Measles and SSPE viruses: similarities and differences.

Authors:  S L Wechsler; H C Meissner
Journal:  Prog Med Virol       Date:  1982

6.  Mechanism of interferon action: phosphorylation of protein synthesis initiation factor eIF-2 in interferon-treated human cells by a ribosome-associated kinase processing site specificity similar to hemin-regulated rabbit reticulocyte kinase.

Authors:  C E Samuel
Journal:  Proc Natl Acad Sci U S A       Date:  1979-02       Impact factor: 11.205

7.  Measles virus polypeptides in infected cells studied by immune precipitation and one-dimensional peptide mapping.

Authors:  M C Graves
Journal:  J Virol       Date:  1981-04       Impact factor: 5.103

8.  A study of measles virus antigens in acutely and persistently infected cells using monoclonal antibodies: differences in the accumulation of certain viral proteins.

Authors:  P Giraudon; C Gerald; T F Wild
Journal:  Intervirology       Date:  1984       Impact factor: 1.763

9.  Persistent and lytic infections with SSPE virus: a comparison of the synthesis of virus-specific polypeptides.

Authors:  J R Stephenson; S G Siddell; V T Meulen
Journal:  J Gen Virol       Date:  1981-11       Impact factor: 3.891

10.  Subacute sclerosing panencephalitis: are antigenic changes involved in measles virus persistence?

Authors:  M J Carter; V Ter Meulen
Journal:  Prog Brain Res       Date:  1983       Impact factor: 2.453

View more
  2 in total

1.  Effect of interferon on Vero cells persistently infected with Sendai virus compared to Vero cells persistently infected with SSPE virus.

Authors:  M Crespi; M N Chiu; J K Struthers; B D Schoub; S F Lyons
Journal:  Arch Virol       Date:  1988       Impact factor: 2.574

2.  In-vitro antiviral efficacy of ribavirin and interferon-alpha against canine distemper virus.

Authors:  Otávio V Carvalho; Giuliana L Saraiva; Caroline G T Ferreira; Daniele M Felix; Juliana L R Fietto; Gustavo C Bressan; Márcia R Almeida; Abelardo Silva Júnior
Journal:  Can J Vet Res       Date:  2014-10       Impact factor: 1.310

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.